Individuals with psychosis and a lifetime history of cannabis use show greater deficits in emotional experience compared to non-using peers
Ashley M. Schnakenberg Martin, Paul H Lysaker
Journal of Mental Health January 2, 2020 DOI: 10.1080/09638237.2018.1487540 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Observational cross-sectional study Peer reviewed |
|---|---|
| Sample size | 71 |
| Population | Adults with schizophrenia, with (n=35) or without (n=36) a lifetime history of cannabis use |
| Measures | Emotional Expressivity Scale (EES), Temporal Experience of Pleasure Scale (TEPS), Social Functioning Scale (SFS) |
| Topics | Cannabis |
| Key findings | Compared with participants without a lifetime history of cannabis use, those with such a history reported lesser ability to express emotion, were less likely to expect pleasure, and had poorer social function. Cannabis use moderated the relationship between anticipatory pleasure and prosocial activities. The authors conclude that lifetime cannabis use may be associated with greater deficits in emotional expressivity, anticipation of pleasure, and social function, and may disrupt the link between anticipatory pleasure and social functioning. |
Abstract
Abstract
Background: While previous research suggests that active cannabis use is a barrier to the emotional experiences of anticipating pleasure and expressing emotion in early psychosis, the relationship between lifetime cannabis use, emotional experience and social function over time has been understudied.
Aims: This study sought to characterize the influence of lifetime cannabis use on emotional experience in prolonged psychosis and the influence of the interaction of cannabis use and emotional expression on social function.
Methods: Emotional expression, experience of pleasure in the moment, anticipatory anhedonia and social functioning were measured concurrently using the Emotional Expressivity Scale (EES), Temporal Experience of Pleasure Scale (TEPS) and Social Functioning Scale (SFS), respectively. Participants were adults with schizophrenia either with (n = 35) or without (n = 36) a lifetime history of cannabis use.
Results: Compared to non-using participants, individuals with a history of cannabis use expressed lesser abilities to express emotion, were less likely to expect pleasure and had poorer social function. Cannabis use moderated the relationship between anticipatory pleasure and prosocial activities.
Conclusions: Lifetime cannabis use in schizophrenia may be associated with greater deficits in emotional expressivity, anticipation of pleasure and social function. Cannabis use may disrupt the relationship between anticipatory pleasure and social functioning.
Comparable studies
Other cross-sectional and survey studies on cannabis, most cited first.
| Study | Year | Design | Participants |
|---|---|---|---|
| Cannabis use before age 15 and subsequent executive functioning 104 chronic cannabis users (49 early-onset before age 15, 55 late-onset after age 15)... | 2011 | Observational cross-sectional study | n = 148 |
| Patterns of simultaneous polysubstance use in drug using university students Drug-using university students | 2006 | Cross-sectional survey | n = 149 |
| Persisting Reductions in Cannabis, Opioid, and Stimulant Misuse After Naturalistic Psychedelic Use: An Online Survey Online survey respondents | 2020 | Cross-sectional survey | |
| User perceptions of the benefits and harms of hallucinogenic drug use: A web-based questionnaire study Users of hallucinogenic drugs who completed a web-based questionnaire | 2010 | Cross-sectional survey | n = 600 |
| Illicit Use of LSD or Psilocybin, but not MDMA or Nonpsychedelic Drugs, is Associated with Mystical Experiences in a Dose-Dependent Manner Adults recruited from the MAPS website and newsletter, most reporting use of various... | 2012 | Cross-sectional survey | n = 337 |
Citations in the library
Cited by 2
Cites 5
- Acute and chronic effects of cannabinoids on effort-related decision-making and reward learning: an evaluation of the cannabis ‘amotivational’ hypotheses Psychopharmacology September 2, 2016
- Altered affective response in marijuana smokers: an FMRI study. Drug and Alcohol Dependence November 1, 2009
- Delta 9-tetrahydrocannabinol induces dopamine release in the human striatum. Neuropsychopharmacology February 2009
- Cannabis use and outcome of recent onset psychosis European Psychiatry June 1, 2005
- Delta-9-tetrahydrocannabinol effects in schizophrenia: implications for cognition, psychosis, and addiction. Biological Psychiatry March 15, 2005